The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis

Contemporary Clinical Trials

Volumn 58, Issue , 2017, Pages 78-85

  Aksamit, Timothy ^a   Bandel, Tiemo Joerg ^b   Criollo, Margarita ^c   De Soyza, Anthony ^d   Elborn, J Stuart ^e   Operschall, Elisabeth ^b   Polverino, Eva ^f   Roth, Katrin ^b   Winthrop, Kevin L ^g   Wilson, Robert ^e  

^a MAYO CLINIC   (United States)

^b BAYER PHARMA AG   (Germany)

^c Bayer Inc   (Canada)

^d FREEMAN HOSPITAL   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Aerosolized antibiotics; Bronchiectasis; Ciprofloxacin Dry Powder for Inhalation; Exacerbations; Randomized controlled trial; Respiratory infections

Indexed keywords

CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; ALLERGIC REACTION; ARTICLE; ASPERGILLOSIS; ATYPICAL MYCOBACTERIOSIS; BRONCHIECTASIS; BRONCHOSPASM; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY POWDER; DRY POWDER INHALER; FEVER; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOPTYSIS; HOSPITALIZATION; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; MICROBIOLOGY; MULTICENTER STUDY; NON CYSTIC FIBROSIS BRONCHIECTASIS; PATHOGEN CLEARANCE; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SPIROMETRY; SPUTUM CULTURE; TENDON DISEASE; TREATMENT DURATION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; METHODOLOGY;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CIPROFLOXACIN; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRY POWDER INHALERS; HUMANS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS;

EID: 85019574569     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2017.05.007     Document Type: Article

References (43)

1. Pasteur, M.C., Bilton, D., Hill, A.T., British Thoracic Society Bronchiectasis non-CF Guideline Group, British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65:Suppl. 1 (2010), 1–58.
2. McDonnell, M.J., Ward, C., Lordan, J.L., Rutherford, R.M., Non-cystic fibrosis bronchiectasis. Q. J. Med. 106 (2013), 709–715.
3. McShane, P.J., Naureckas, E.T., Tino, G., Strek, M.E., Non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 188 (2013), 647–656.
4. Cole, P.J., Inflammation: a two-edged sword – the model of bronchiectasis. Eur. J. Respir. Dis. Suppl. 147 (1986), 6–15.
5. Chalmers, J.D., Aliberti, S., Blasi, F., Management of bronchiectasis in adults. Eur. Respir. J. 45 (2015), 1446–1462.
6. Roberts, J.H., Hubbard, R., Trends in bronchiectasis mortality in England and Wales. Respir. Med. 104 (2010), 981–985.
7. Loebinger, M.R., Wells, A.U., Hansell, D.M., Chinyanganya, N., Devaraj, A., Meister, M. et al., Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur. Respir. J. 34 (2009), 843–849.
8. Quint, J.K., Millett, E.R., Joshi, M., Navaratnam, V., Thomas, S.L., Hurst, J.R. et al., Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur. Respir. J. 47 (2016), 186–193.
9. Wilson, C.B., Jones, P.W., O'Leary, C.J., Cole, P.J., Wilson, R., Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am. J. Respir. Crit. Care Med. 156 (1997), 536–541.
10. Goeminne, P.C., Scheers, H., Decraene, A., Seys, S., Dupont, L.J., Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir. Res., 13, 2012, 21.
11. Chalmers, J.D., Goeminne, P., Aliberti, S., McDonnell, M.J., Lonni, S., Davidson, J. et al., The Bronchiectasis Severity Index. An international derivation and validation study. Am. J. Respir. Crit. Care Med. 189 (2014), 576–585.
12. Martinez-Garcia, M.A., Soler-Cataluña, J.J., Perpina-Tordera, M., Roman-Sanchez, P., Soriano, J., Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132 (2007), 1565–1572.
13. Barker, A.F., O'Donnell, A.E., Flume, P., Thompson, P.J., Ruzi, J.D., de Gracia, J. et al., Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised, double-blind, placebo-controlled phase III trials. Lancet Respir. Med. 2 (2014), 738–749.
14. Martinez-Garcia, M.A., de Gracia, J., Relat, M.V., Giron, R.-M., Carro, L.M., de la Rosa, Carrillo D. et al., Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur. Respir. J. 43 (2014), 1357–1367.
15. De Soyza, A., Brown, J.S., Loebinger, M.R., Bronchiectasis Research & Academic Network, Research priorities in bronchiectasis. Thorax 68 (2013), 695–696.
16. Polverino, E., Cacheris, W., Spencer, C., Operschall, E., O'Donnell, A., Global burden of non-cystic fibrosis bronchiectasis: a simple epidemiological analysis. Eur. Respir. J., 40(Suppl. 56), 2012.
17. Bilton, D., Daviskas, E., Anderson, S.D., Kolbe, J., King, G., Stirling, R.G. et al., Phase III randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 144 (2013), 215–225.
18. Bilton, D., Tino, G., Barker, A.F., Chambers, D.C., De Soyza, A., Dupont, L.J.A. et al., Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 69 (2014), 1073–1079.
19. Haworth, C.S., Foweraker, J.E., Wilkinson, P., Kenyon, R.F., Bilton, D., Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 189 (2014), 975–982.
20. O'Donnell, A.E., Barker, A.F., Ilowite, J.S., Fick, R.B., rh DNase Study Group, Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest 113 (1998), 1329–1334.
21. Metersky, M.L., O'Donnell, A.E., Nebulized colistin for non-cystic fibrosis bronchiectasis: déjà vu all over again?. Am. J. Respir. Crit. Care Med. 189 (2014), 115–121.
22. ElMaraachli, W., Conrad, D.J., Wang, A.C., Using cystic fibrosis therapies for non-cystic fibrosis bronchiectasis. Clin. Chest Med. 37 (2016), 139–146.
23. Murray, M.P., Govan, J.R.W., Doherty, C.J., Simpson, J., Wilkinson, T.S., Chalmers, J.D. et al., A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 183 (2011), 491–499.
24. Wong, C., Jayaram, L., Karalus, N., Eaton, T., Tong, C., Hockey, H. et al., Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 380 (2012), 660–667.
25. Altenburg, J., de Graaff, C.S., Stienstra, Y., Sloos, J.H., van Haren, E.H., Koppers, R.J. et al., Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. The BAT randomized controlled trial. JAMA 309 (2013), 1251–1259.
26. Serisier, D.J., Martin, M.L., McGuckin, M.A., Lourie, R., Chen, A.C., Brain, B. et al., Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. The BLESS randomized controlled trial. JAMA 309 (2013), 1260–1267.
27. Wu, Q., Shen, W., Cheng, H., Zhou, X., Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology 19 (2014), 321–329.
28. Weers, J., Inhaled antimicrobial therapy – barriers to effective treatment. Adv. Drug Deliv. Rev. 85 (2015), 24–43.
29. Wilson, R., Welte, T., Polverino, E., De Soyza, A., Greville, H., O'Donnell, A. et al., Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur. Respir. J. 41 (2013), 1107–1115.
30. Hurst, J.R., Elborn, J.S., De Soyza, A., BRONCH-UK Consortium, COPD-bronchiectasis overlap syndrome. Eur. Respir. J. 45 (2015), 310–313.
31. Henkle, E., Daley, C.L., Griffith, D.E., Walsh, J.W., Leitman, P., Malanga, E. et al., Patterns of pharmacotherapy for non-cystic fibrosis bronchiectasis [abstract]. Am. J. Respir. Crit. Care Med., 191, 2015, A2445.
32. Hill, A.T., Routh, C., Welham, S., National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care?. Thorax 69 (2014), 292–294.
33. Guan, W.J., Gao, Y.H., Xu, G., Lin, Z.Y., Tang, Y., Li, H.M. et al., Characterization of lung function impairment in adults with bronchiectasis. PLoS One, 9, 2014, e113373.
34. Finch, S., McDonnell, M.J., Abo-Leyah, H., Aliberti, S., Chalmers, J.D., A comprehensive analysis of the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 12 (2015), 1602–1611.
35. McDonnell, M.J., Jary, H.R., Perry, A., MacFarlane, J.G., Hester, K.L., Small, T. et al., Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational study of Pseudomonas persistence and resistance. Respir. Med. 109 (2014), 716–726.
36. Chalmers, J.D., Smith, M.P., McHugh, B.J., Doherty, C., Govan, J.R., Hill, A.T., Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 186 (2012), 657–665.
37. De Soyza, A., Aksamit, T., Operschall, E., Bandel, T., Krahn, U., Criollo, M. et al., Baseline demographic profile of subjects of the phase III RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB) [poster]. Eur. Respir. Soc. Congr., 2015, A2617.
38. Aksamit, T., Bandel, T.J., Criollo, M., De Soyza, A., Elborn, J.S., Montegriffo, E., Operschall, E., Polverino, E., Winthrop, K., Wilson, R., Baseline profiles of patients randomized in RESPIRE 2 trial of Ciprofloxacin Dry Powder for Inhalation (DPI) in non-CF bronchiectasis by pathogen and prior exacerbation rate [poster]. Eur. Respir. Soc. Congr., 2016, PA155.
39. Flume, P.A., VanDevanter, D.R., Clinical applications of pulmonary delivery of antibiotics. Adv. Drug Deliv. Rev. 85 (2015), 1–6.
40. Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J. et al., Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 340 (1999), 23–30.
41. Ramsey, B.W., Dorkin, H.L., Eisenberg, J.D., Gibson, R.L., Harwood, I.R., Kravitz, R.M. et al., Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328 (1993), 1740–1746.
42. Barker, A.F., Couch, L., Fiel, S.B., Gotfried, M.H., Ilowite, J., Meyer, K.C. et al., Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 162 (2000), 481–485.
43. Dorkin, H.L., Staab, D., Operschall, E., Alder, J., Criollo, M., Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis. BMJ Open Respir. Res., 2015, 10.1136/bmjresp-2015-000100.